SpringWorks Therapeutics (SWTX) Set to Announce Quarterly Earnings on Thursday

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) is scheduled to be releasing its earnings data before the market opens on Thursday, May 2nd. Analysts expect SpringWorks Therapeutics to post earnings of ($1.19) per share for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last released its earnings results on Tuesday, February 27th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by ($0.20). The firm had revenue of $5.45 million during the quarter, compared to the consensus estimate of $1.26 million. During the same period in the previous year, the company posted ($1.19) earnings per share. On average, analysts expect SpringWorks Therapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

SpringWorks Therapeutics Trading Up 1.9 %

Shares of SWTX traded up $0.82 on Thursday, reaching $44.20. 999,777 shares of the company's stock traded hands, compared to its average volume of 1,097,333. The stock's 50 day simple moving average is $47.75 and its two-hundred day simple moving average is $37.61. SpringWorks Therapeutics has a 52-week low of $18.00 and a 52-week high of $53.92. The stock has a market cap of $3.26 billion, a PE ratio of -8.60 and a beta of 0.83.

Insiders Place Their Bets

In other news, insider Daniel Pichl sold 15,000 shares of SpringWorks Therapeutics stock in a transaction on Friday, February 16th. The stock was sold at an average price of $50.10, for a total value of $751,500.00. Following the completion of the transaction, the insider now directly owns 45,212 shares in the company, valued at $2,265,121.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 7.61% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SWTX. HC Wainwright raised their price target on shares of SpringWorks Therapeutics from $73.00 to $74.00 and gave the stock a "buy" rating in a research note on Wednesday, March 6th. JPMorgan Chase & Co. boosted their target price on SpringWorks Therapeutics from $73.00 to $74.00 and gave the company an "overweight" rating in a research note on Wednesday, March 6th. Barclays upped their price target on SpringWorks Therapeutics from $47.00 to $63.00 and gave the company an "overweight" rating in a research report on Thursday, February 29th. Wedbush lifted their price objective on SpringWorks Therapeutics from $60.00 to $70.00 and gave the stock an "outperform" rating in a report on Monday, February 26th. Finally, Guggenheim started coverage on SpringWorks Therapeutics in a research note on Monday, February 5th. They issued a "buy" rating and a $75.00 price objective on the stock. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $68.00.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.